New Rewards Coming Soon!¡Se vienen nuevas recompensas!
Our Healthy Rewards Program is getting an update in September! For a sneak peek of all the changes - including new rewards and ways to redeem them - please click here.
¡Nuestro Programa Healthy Rewards tendrá su actualización en septiembre! Para ver un adelanto de todos los cambios, incluyendo nuevas recompensas y formas de canjearlas, haz clic aquí.
Temporary Change in PDL Status for Antihypertensives, Sympatholytics Drug Class
Date: September 26, 2022 Attention: All Providers Effective Date: September 26, 2022Providers should monitor the Texas Children’s Health Plan (TCHP) Provider Portal regularly for alerts and updates associated to the COVID-19 event. TCHP reserves the right to update and/or change this information without prior notice due to the evolving nature of the COVID-19 event.
Call to action: The Health and Human Services Commission (HHSC) is aware of a drug shortage for Catapres-TTS patches in the Antihypertensives, Sympatholytics drug class due to the discontinuation of this product by the manufacturer, Boehringer Ingelheim. HHSC received reports of a shortage from MCOs, and the manufacturer verified the shortage.
How this impacts providers: Effective September 26, 2022, HHSC temporarily removed the non-preferred status from the generic product, clonidine transdermal patches, on the preferred drug list (PDL). The preferred status of the brand name products (NDC 00597-0031-34, 00597-0032-34, and 00597-0033-34) will not change to allow for any existing stock available to be utilized.
HHSC removed the non-preferred status for the following generic drugs.
